Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL

Dimensional Fund Advisors LP increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 11.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,180,912 shares of the biotechnology company’s stock after acquiring an additional 419,596 shares during the quarter. Dimensional Fund Advisors LP owned about 1.56% of Exelixis worth $172,658,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Exelixis by 81.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. raised its stake in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the last quarter. Focus Partners Wealth boosted its stake in Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after buying an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC lifted its position in Exelixis by 23.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after acquiring an additional 2,764 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Price Performance

EXEL opened at $42.37 on Tuesday. The company has a 50 day simple moving average of $43.51 and a two-hundred day simple moving average of $41.62. The firm has a market cap of $11.00 billion, a P/E ratio of 15.30, a PEG ratio of 0.93 and a beta of 0.41. Exelixis, Inc. has a 1-year low of $32.38 and a 1-year high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The firm had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the firm earned $0.55 EPS. The company’s revenue was up 5.6% on a year-over-year basis. Equities analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insiders Place Their Bets

In other Exelixis news, EVP Dana Aftab sold 47,918 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the sale, the executive vice president directly owned 616,106 shares of the company’s stock, valued at $27,416,717. This trade represents a 7.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the transaction, the executive vice president directly owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. This trade represents a 15.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 362,849 shares of company stock worth $15,917,463 in the last three months. 2.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. HC Wainwright upped their target price on shares of Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Wells Fargo & Company upped their price objective on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. Truist Financial set a $51.00 target price on Exelixis in a report on Wednesday, January 14th. Finally, UBS Group set a $41.00 target price on Exelixis in a research report on Monday, January 5th. Ten research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $46.94.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.